Expression of G3BP1 correlates with YB-1 and is linked to poor outcomes. (A) Serial sections of three TMAs containing 153 different human sarcoma cases were subjected to sequential IHC using antibodies to YB-1 or G3BP1 as indicated. Panels show expression of YB-1 and G3BP1 by IHC in four different representative sarcoma cases. Insets show 10-fold higher magnification of representative areas. Immunostaining for each protein was scored as no (0), low (1+), moderate (2+), or high expression (3+) as indicated. Bars: (main panels) 100 µm; (enlarged insets) 20 µm. (B) Tabulated values from IHC scoring of A, with a Spearman’s rank correlation coefficient between expression of each protein of 0.4963 and a p-value of 0.0001437. (C and D) Kaplan-Meier estimates for overall survival (event = deceased) in relation to G3BP1 expression for Ewing sarcoma patients with localized disease (high and medium vs. low G3BP1 expression; C) and metastatic disease (high vs. low and medium G3BP1 expression; D).